Carbapenem-resistant gram-negative bacteria consistently top the list of deadliest multidrug-resistant organisms, with mortality rates in intensive care settings regularly exceeding 40% and sometimes climbing past 70%. The organisms that kill at the highest rates are not necessarily the ones the public hears about most. MRSA gets the headlines, but carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Enterobacterales, and drug-resistant Candida auris are, in many clinical settings, substantially more lethal. The picture is complicated by the fact that the same bug can be a minor nuisance in one patient and a death sentence in another, depending on infection site, immune status, and how quickly the right treatment starts.
Carbapenem-Resistant Acinetobacter baumannii
If there is a single organism that infectious disease specialists dread, it is carbapenem-resistant Acinetobacter baumannii, or CRAB. This bacterium thrives on hospital surfaces and ventilator circuits, and once it becomes resistant to carbapenems, the strongest broad-spectrum antibiotics available, treatment options shrink dramatically. A prospective study of fifty ICU patients with confirmed CRAB infections found that 40% died, and clinical improvement occurred in only half. The study authors described frequent panresistance, meaning the bacteria were resistant to essentially every drug tested.1JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH. Clinical Profile and Outcome in Patients Infected with Carbapenem-resistant Acinetobacter baumannii Infection in ICU Setting: A Prospective Observational Study
That 40% figure may actually understate the problem. A study in a Moroccan teaching hospital reported crude mortality of about 74% among ICU patients with A. baumannii infections, with septic shock and older age being the strongest predictors of death.2PubMed Central. Intensive care unit-acquired Acinetobacter baumannii infections in a Moroccan teaching hospital: epidemiology, risk factors and outcome The range reflects real differences in patient populations and available therapies, but even the lower end is sobering. CRAB is particularly devastating because it often strikes patients who are already critically ill, on ventilators, or recovering from major surgery, and the treatment toolkit for it remains thin.
Carbapenem-Resistant Enterobacterales
Carbapenem-resistant Enterobacterales, or CRE, is a family of gut bacteria that includes Klebsiella pneumoniae, Escherichia coli, and Enterobacter species. The CDC once dubbed CRE “nightmare bacteria,” and the mortality data support the label. A multicenter study of patients with CRE bloodstream infections found an overall 30-day mortality rate of about 51%.3Scientific Reports. Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: a multicenter propensity-score matched study Other studies place 30-day mortality in the range of 39% to 42%, with sepsis at the time of diagnosis, pneumonia as the infection source, and inappropriate initial antibiotic choice all sharply increasing the odds of death.4PubMed Central. Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection5PubMed Central. Assessment of Mortality-Related Risk Factors and Effective Antimicrobial Regimens for Treatment of Bloodstream Infections Caused by Carbapenem-Resistant Enterobacterales
Klebsiella pneumoniae deserves special mention within the CRE group. Some strains carry “hypervirulence” genes that help the bacteria evade immune defenses and invade tissues more aggressively. When hypervirulence and carbapenem resistance combine in the same strain, the median mortality sits around 30%, though the range across published studies is wide.6PubMed. Prevalence, mortality, risk factors, and treatment of carbapenem-resistant hypervirulent Klebsiella pneumoniae: an evidence map Interestingly, head-to-head comparisons of hypervirulent versus classical carbapenem-resistant Klebsiella have not always found a statistically significant difference in death rates, suggesting that carbapenem resistance itself is the dominant driver of mortality rather than the extra virulence genes alone.7The Journal of Infectious Diseases. Clinical Outcomes in Hypervirulent Carbapenem-Resistant Klebsiella pneumoniae Infection: A Cohort Study
Drug-Resistant Pseudomonas and Stenotrophomonas
Pseudomonas aeruginosa is an opportunistic pathogen with an inherent talent for resisting antibiotics. It causes ventilator-associated pneumonia, wound infections, and bloodstream infections, particularly in burn units and ICUs. The carbapenem-resistant phenotype roughly quadruples the odds of dying compared to susceptible strains, and both carbapenem-resistant and multidrug-resistant phenotypes are linked to higher early mortality within the first five days of bloodstream infection.8PubMed Central. Risk Factors for Mortality of Inpatients with Pseudomonas aeruginosa Bacteremia in China: Impact of Resistance Profile in the Mortality Looking at longer-term outcomes, a cohort study of patients with multidrug-resistant P. aeruginosa in the urinary tract found an overall mortality of about 17%, with roughly a third of those deaths estimated to be directly tied to the resistant infection.9PubMed Central. Long-Term Outcomes of Multidrug-Resistant Pseudomonas aeruginosa Bacteriuria: A Retrospective Cohort Study
Stenotrophomonas maltophilia is less well known but increasingly recognized as a serious threat, especially in patients with blood cancers or those on prolonged ICU stays. This organism is intrinsically resistant to carbapenems and many other drug classes, making it difficult to treat from the outset. Studies report 28-day mortality rates for S. maltophilia bloodstream infections ranging from about 35% to 46%.10PubMed Central. Risk Factors for Mortality in Hospitalized Patients with Stenotrophomonas maltophilia Bacteremia11Infection Control & Hospital Epidemiology. Hospital Infections by Stenotrophomonas maltophilia: Results in Five Years of Multicentric Study In patients with blood disorders, prolonged neutropenia and ceftazidime resistance independently worsen the prognosis.12PubMed Central. Predictors of mortality and progression from colonization to Stenotrophomonas maltophilia bloodstream infection in hematologic disorders: a single-center retrospective study
MRSA and Its Lingering Toll
Methicillin-resistant Staphylococcus aureus is probably the most publicly recognized MDRO, and it remains a major killer, though its headline mortality rates are lower than those of the gram-negative organisms described above. Within a year of diagnosis, roughly 22% of patients with community-diagnosed MRSA infections died, compared with 5% of patients with non-MRSA Staphylococcus aureus, giving MRSA patients about four times the risk of death after adjustment.13PubMed Central. Mortality after infection with methicillin-resistant Staphylococcus aureus (MRSA) diagnosed in the community
What makes MRSA distinctive is how much of its mortality is delayed. A study tracking patients after their initial Staph infection found that at three months post-discharge, MRSA patients had a mortality rate of 32% versus 18% for those with methicillin-susceptible strains. By twelve months, the gap had widened further: 51% versus 32%.14PubMed. Long-term outcomes following infection with meticillin-resistant or meticillin-susceptible Staphylococcus aureus Most deaths occurred after hospital discharge, not during the initial stay. This long tail of excess mortality is easy to miss when studies only track in-hospital outcomes, and it means that MRSA’s true burden is larger than the acute mortality numbers suggest.
Vancomycin-Resistant Enterococci
Enterococci are gut bacteria that occasionally cause bloodstream infections, urinary tract infections, and infections of the heart valves. When they develop vancomycin resistance, especially the species E. faecium, mortality climbs substantially. A systematic review found that 30-day mortality for vancomycin-resistant enterococcal bloodstream infections ranged from about 28% at the low end to 70% at the high end, depending on the patient population and study setting.15Journal of Hospital Infection. Epidemiology and outcomes of vancomycin-resistant enterococcus infections: a systematic review and meta-analysis Compared head to head with vancomycin-susceptible strains, resistance nearly doubles the hazard of dying.16PubMed Central. Does Vancomycin Resistance Increase Mortality? Clinical Outcomes and Predictive Factors for Mortality in Patients with Enterococcus faecium Infections
VRE disproportionately affects patients in oncology wards, transplant units, and long-stay ICU beds. One study found 28-day mortality of about 51% among patients with vancomycin-resistant E. faecium bacteremia.17PubMed. Clinical characteristics and treatment outcomes of vancomycin-resistant Enterococcus faecium bacteremia The bacteria themselves are sometimes less virulent than gram-negative pathogens, but the patients they infect tend to be profoundly immunocompromised, and the loss of vancomycin as a treatment option leaves clinicians relying on drugs with narrower effectiveness and more side effects.
Candida auris
Not all deadly MDROs are bacteria. Candida auris, a yeast first identified in Japan in 2009, has since spread to hospitals on every inhabited continent and quickly earned a reputation as one of the most dangerous hospital-acquired fungal infections. It resists multiple classes of antifungal drugs, persists on surfaces for weeks, and spreads readily between patients. In a large U.S. hospital database covering 2017 to 2022, the estimated crude mortality for C. auris-associated hospitalizations was 34%.18Emerging Infectious Diseases. Candida auris‒Associated Hospitalizations, United States, 2017–2022
Published estimates of mortality from C. auris bloodstream infections range widely, from about 29% to 62%, depending on the setting.19Medical Mycology. Candida auris—a systematic review to inform the world health organization fungal priority pathogens list One multicenter cohort that compared C. auris directly with other Candida species found that after adjusting for treatment and septic shock, C. auris bloodstream infection actually carried somewhat lower mortality than infections from other Candida species combined.20PubMed Central. Mortality Caused by Candida auris Bloodstream Infections in Comparison with Other Candida Species, a Multicentre Retrospective Cohort The raw numbers look high partly because C. auris tends to infect the sickest patients in the hospital. That does not make it less dangerous in practice, since those are exactly the patients who can least afford an untreatable infection, but it does mean that the organism itself may not be inherently more lethal than other Candida species once you account for how fragile its hosts already are.
Multidrug-Resistant Tuberculosis
MDR-TB belongs in a separate conversation from the hospital-acquired organisms above, because tuberculosis is a community-transmitted disease with a treatment course measured in months or years rather than days. But its death toll is enormous. Globally, antimicrobial resistance across all pathogens was responsible for roughly 1.14 million deaths directly attributable to resistance in 2021, with millions more associated deaths.21PubMed Central. Global burden of bacterial antimicrobial resistance 1990–2021: a systematic analysis with forecasts to 2050 MDR-TB is one of the single largest contributors to that total.
Compared with drug-susceptible tuberculosis, MDR-TB multiplies the risk of dying during treatment roughly sevenfold.22PubMed Central. Mortality among MDR-TB Cases: Comparison with Drug-Susceptible Tuberculosis and Associated Factors A long-term follow-up study in Wuhan, China found that about 40% of MDR-TB patients died during follow-up, with older age, lower education level, and treatment interruption all raising the risk substantially.23Journal of Infection and Public Health. Higher mortality rate amongst multidrug-resistant tuberculosis patients with non-standard treatment: A long-term follow-up study in Wuhan, China In settings with access to newer short-course regimens, outcomes can be better: an Indonesian study reported that roughly 9% of MDR-TB patients on short-course treatment died, though older patients still faced markedly higher risk.24Journal of Public Health and Development. Effect of age, gender, and linezolid use on MDR-TB Patient survival rate with short-course treatment in Central Java, Indonesia: survival analysis and cox regression The gap between 9% and 40% illustrates how much treatment access and adherence shape outcomes in MDR-TB, far more than for many hospital-acquired MDROs where even optimal therapy may not save the patient.
Why Resistance Makes Infections So Much Deadlier
The obvious explanation is that when the usual drugs do not work, doctors have fewer options and some patients get no effective treatment at all. But the mechanism goes beyond just running out of antibiotics. A big part of the mortality penalty comes from timing. In sepsis, every hour of delay in receiving an effective antibiotic increases the odds of dying. A meta-analysis found that each hour of delayed antibiotic treatment raised in-hospital mortality by about 4%, and giving antibiotics after the first hour rather than within it raised mortality by about 20%.25PubMed. Effect of delayed antibiotic use on mortality outcomes in patients with sepsis or septic shock: A systematic review and meta-analysis In patients with septic shock, a large multicenter study estimated that each hour of delay added about 1.8 percentage points to absolute mortality.26PubMed Central. The Timing of Early Antibiotics and Hospital Mortality in Sepsis
When a patient has an MDRO infection, the empiric antibiotics given at admission, chosen before lab results come back, are more likely to be the wrong ones. By the time cultures confirm which organism is present and which drugs still work, hours or days have passed. This gap between infection onset and effective treatment is the single biggest mechanism by which resistance kills. In multiple CRE studies, inappropriate empiric therapy was independently associated with dying, with one analysis showing it roughly quintupled the odds of death.4PubMed Central. Mortality rate and factors associated with mortality of carbapenem-resistant Enterobacteriaceae infection
The remaining drugs for highly resistant infections also tend to be more toxic, harder to dose correctly, and less effective. Colistin, one of the last-resort antibiotics for gram-negative MDROs, damages the kidneys. Linezolid, used against VRE and MRSA, suppresses bone marrow. Patients are caught between the infection and the side effects of salvage therapy.
Populations at Greatest Risk
MDROs hit hardest in people whose immune defenses are already weakened. Solid organ transplant recipients are a stark example. A meta-analysis found that colonization with multidrug-resistant bacteria before or after transplant more than doubled the risk of dying within a year. Colonization with CRE was the most dangerous, nearly quadrupling one-year mortality, while MRSA colonization roughly doubled it.27Clinical Microbiology and Infection. The impact of colonization by multidrug resistant bacteria on graft survival, risk of infection, and mortality in recipients of solid organ transplant: systematic review and meta-analysis Liver transplant recipients seem particularly vulnerable, partly because the surgical site is close to the gut where resistant bacteria reside.28PubMed Central. Multidrug-resistant bacterial infections after liver transplantation: an ever-growing challenge
Newborns in intensive care are another highly susceptible group. A study comparing neonates with multidrug-resistant gram-negative sepsis to those with susceptible strains found that case fatality was roughly 3.6 times higher in the resistant group, and septic shock rates were dramatically elevated.29PubMed. Multidrug-resistant Gram-negative bacilli sepsis from a neonatal intensive care unit: a case-case-control study Premature infants, whose immune systems are underdeveloped and who often need prolonged IV access, are at especially high risk for acquiring these organisms.
COVID-19 hospitalization revealed another dimension of vulnerability. In a study of nearly 500 patients with COVID-19 pneumonia, those who developed secondary hospital-acquired infections from MDROs had in-hospital mortality of about 84%, compared with roughly 22% for COVID-19 patients without MDRO superinfections.30PubMed Central. Healthcare-Associated Infections Secondary to Multidrug-Resistant Organisms in Hospitalised Patients with COVID-19 Pneumonia: A single-centre experience This fourfold difference underscores how MDRO infections pile on top of existing critical illness, creating a compounded threat that overwhelms even aggressive supportive care.
New Treatments and Their Limits
The antibiotic pipeline has not been entirely dry. Newer beta-lactam/beta-lactamase inhibitor combinations like ceftazidime-avibactam have become important weapons against CRE, especially Klebsiella pneumoniae. A single-center study of 142 patients with carbapenem-resistant K. pneumoniae infections treated with ceftazidime-avibactam found a 28-day survival rate of 78%.31PubMed Central. Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Klebsiella Pneumoniae Infection: A Retrospective, Single Center Study That represents a meaningful improvement over historical mortality rates for CRE, though more than one in five patients still died.
The problem is that resistance follows treatment. In one study of carbapenem-resistant Klebsiella pneumoniae from ventilator-associated pneumonia, 79% of isolates were already resistant to ceftazidime-avibactam. A newer drug, cefiderocol, maintained activity against 96% of the same isolates, offering a backup option, but its long-term resistance trajectory remains uncertain.32PubMed Central. Carbapenem-Resistant Klebsiella pneumoniae Among Patients with Ventilator-Associated Pneumonia: Evaluation of Antibiotic Combinations and Susceptibility to New Antibiotics The pattern is familiar: a new drug arrives, works well for a few years, and then resistance begins to erode its effectiveness. The pharmaceutical development cycle for antibiotics is slow relative to how quickly bacteria adapt.
What Happens When Every Drug Fails
Pan-drug-resistant organisms, those resistant to every available antibiotic, are no longer hypothetical. They appear sporadically in ICUs worldwide, and modeling studies have tried to estimate the consequences of their broader spread. A modeling study focused on E. coli projected that mortality from a hypothetical pan-resistant strain causing sepsis could reach anywhere from 34% to 96% in adults over 65, depending on assumptions about supportive care and host factors.33Communications Medicine. Predicting sepsis mortality into an era of pandrug-resistant E. coli through modeling Even the low end of that range is devastating for what is currently a routinely treatable bacterium.
In clinical practice, a retrospective ICU study comparing patients with extensively drug-resistant or pan-drug-resistant gram-negative infections to those with less resistant strains found longer ICU stays, more vasopressor use, and higher raw mortality. Yet resistance phenotype alone did not independently predict death in the multivariate analysis, suggesting that the severity of the underlying illness still matters more than the resistance profile in determining who survives.34PubMed Central. Prevalence, Clinical Severity, and Outcomes of Extensively Drug-Resistant and Pan-Drug-Resistant Gram-Negative Infections in a Tertiary Intensive Care Unit: A Retrospective Observational Study That finding is a reminder that resistance and mortality are tangled up with how sick the patient already is. The most resistant organisms tend to appear in the most debilitated patients, making it hard to separate how much of the death rate is driven by the bug versus the host.
Long-Term Care and the Mortality That Gets Missed
Much of the research on MDRO mortality focuses on acute hospitalization, but a substantial portion of the burden unfolds later, in rehabilitation facilities, long-term care, and after discharge. MRSA patients, as noted earlier, continue dying at elevated rates for a full year after their initial infection. A prospective study in a long-term care facility found that mortality among MDRO-colonized residents depended more on sputum carriage and the resident’s overall health than on which specific resistant organism they carried.35PubMed. Hierarchical multilevel prospective study of multidrug-resistant organisms: Decolonization, mortality, and co-colonization in a long-term care facility In other words, simply carrying a resistant organism in the gut or on the skin is not itself a death sentence, but once it causes active infection in a frail host, the outcomes are poor and the ripple effects extend well beyond the initial hospital stay.
This post-acute mortality is systematically undercounted. Hospital databases capture in-patient deaths, but a patient discharged alive after CRE bacteremia who dies three weeks later at a skilled nursing facility may never appear in the hospital’s mortality statistics. Studies that follow patients for 90 days or a year consistently find higher overall death tolls than 30-day studies, which means the commonly cited 30-day mortality rates for most MDROs, while already alarming, underestimate the full impact of these infections on survival.